Table 2B. Univariate and multivariable analysis of predictors of PFS in patients treated with first-line therapy for locally advanced or metastatic NSCLC.

PROGRESSION-FREE SURVIVAL IN THE OVERALL POPULATION
	Univariate Cox Regression		Multivariable Cox regression
	HR (95%CI)	p-value	HR (95%CI)	p-value
Age (≥ 70y vs. < 70y)	0.99 (0.79−1.25)	0.964
Gender (F vs. M)	0.82 (0.64−0.99)	0.111	0.83 (0.64−1.08)	0.171
ECOG-PS (≥ 2 vs. < 2)	1.39 (0.90−2.14)	0.139	1.26 (0.80−1.97)	0.316
Smoke status (N vs. Y)	0.90 (0.67−1.21)	0.486
Tumor Stage (IV vs. III)	1.36 (1.05−1.75)	0.020	1.41 (1.09−1.83)	0.010
Histology (AC vs. non-AC)	0.91 (0.72−1.15)	0.433
EGFR Status (WT vs. MT)	0.62 (0.42−0.92)	0.018	0.63 (0.42−0.95)	0.027
Hyponatremia (Y vs. N)	1.23 (0.87−1.73)	0.245

Significant values are reported in bold.

AC = Adenocarcinoma; CI = confidence interval; ECOG-PS = Eastern Cooperative Oncology Group Performance Status; EGFR = Epidermal growth factor receptor; F = female; HR = hazard ratio; M = male; MT = mutated status; WT = wild-type status